Полатузумаб ведотин в терапии диффузной В-клеточной крупноклеточной лимфомы: обзор литературы и опыт отделения онкогематологии Клинического госпиталя «Лапино»

Изучение молекулярно-генетических особенностей диффузной В-клеточной крупноклеточной лимфомы (ДВККЛ) предполагает применение дифференцированного подхода к лечению агрессивного В-клеточного заболевания, характеризующегося
непродолжительной ремиссией при каждой последующей линии терапии. В связи с этим целесообразно использование более эффективных режимов на ранних этапах заболевания. Выделение биологических маркеров и интеграция их в используемые
прогностические шкалы могут способствовать персонализированному подходу к терапии, особенно у пациентов с высоким риском быстрого прогрессирования, и увеличению выживаемости. Представлен собственный опыт применения иммуноконъюгата полатузумаба ведотина в терапии больных с ДВККЛ. Использование комбинации Pola-BR у пациента с non-GCB-вариантом рефрактерной ДВККЛ обеспечило достижение полной ремиссии наряду с удовлетворительной переносимостью и отсутствием значимых нежелательных явлений. Дана оценка применению режима Pola-R-CHP при лечении больного с впервые диагностированным GCB-вариантом генерализованной ДВККЛ

1. Ruppert A.S., Dixon J.G., Salles G. et al. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood 2020;135(23):2041–8. DOI: 10.1182/blood.2019002729

2. Sehn L.H., Salles G. Diffuse large B-cell lymphoma. N Engl J Med 2021;384(9):842–58. DOI: 10.1056/NEJMra2027612

3. WHO classification of tumours oh haematopoetic and lymphoid tissues. Ed. by S.H. Swerdlov, E. Campo, N.L. Harris et al. Revised 4th edn. WHO Press, 2017.

4. Scott D.W., King R.L., Staiger A.M. et al. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology. Blood 2018;131(18):2060–4. DOI: 10.1182/blood-2017-12-820605

5. Rosenwald A., Bens S., Advani R. et al. Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2019;37(35):3359–68. DOI: 10.1200/JCO.19.00743

6. Hu S., Xu-Monette Z.Y., Tzankov A. et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-CHOP Consortium Program. Blood 2013;121(20):4021–31. DOI: 10.1182/blood-2012-10-460063

7. Savage K.J., Slack G.W., Mottok A. et al. Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL. Blood 2016;127(18):2182–8. DOI: 10.1182/blood-2015-10-676700

8. Devi K., Shaikh M.U., Ali N.B. et al. Outcomes of patients with double/triple expressor diffuse large B-cell lymphoma (DLBCL) treated with R-DA-EPOCH/R-CHOP: a single-center experience. Leuk Res Rep 2021;16:100284. DOI: 10.1016/j.lrr.2021.100284

9. Ma Q., Chang Y., Li L. et al. Efficacy of dose-adjusted EPOCH plus rituximab/R-CHOP regimens and the prognosis analysis in patients with MYC, BCL2/BCL6 gene copy number gain lymphoma and double-hit lymphoma: results from a single institution retrospective clinical study. Cancer Manag Res 2019;11:1363–72. DOI: 10.2147/CMAR.S192143

10. Chen Y., Cai Q., Chang Yu. et al. High-intensity chemotherapy improved the prognosis of patients with high-grade B-cell lymphoma. Front Immunol 2022;13:1047115. DOI: 10.3389/fimmu.2022.1047115

11. Nowakowski G.S., Chiappella A., Gascoyne R.D. et al. ROBUST: a phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma. J Clin Oncol 2021;39(12):1317–28. DOI: 10.1200/JCO.20.01366

12. Davies A., Cummin T.E., Barrans S. et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol 2019;20(5):649–62. DOI: 10.1016/S1470-2045(18)30935-5

13. Younes A., Sehn L.H., Johnson P. et al. Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. J Clin Oncol 2019;37(15):1285–95. DOI: 10.1200/JCO.18.02403

14. Crump M., Neelapu S., Farooq U. et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 2017;130(16):1800–8. DOI: 10.1182/blood-2017-03-769620

15. Sawalha Y., Maddocks K. Profile of polatuzumab vedotin in the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: a brief report on the emerging clinical data. Onco Targets Ther 2020;13:5123–33. DOI: 10.2147/OTT.S219449

16. Инструкция по медицинскому применению препарата Полатузумаб ведотин, ЛП-006599.

17. Polson A.G., Yu S.F., Elkins K. et al. Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma. Blood 2017;110(2):616–23. DOI: 10.1182/blood-2007-01-066704

18. Papageorgiou S.G., Thomopoulos T.P., Liaskas A., Vassilakopoulos T.P. Antibodies in the treatment of diffuse large B-cell lymphoma: moving beyond rituximab. Cancers (Basel) 2022;14(8):1917. DOI: 10.3390/cancers14081917

19. Assi R., Masri N., Dalle I.A. et al. Polatuzumab vedotin: current role and future applications in the treatment of patients with diffuse large B-cell lymphoma. Clin Hematol Int 2021;3(1):21–6. DOI: 10.2991/chi.k.210305.001

20. Palanca-Wessels M.C., Czuczman M., Salles G. et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015;16(6):704–15. DOI: 10.1016/S1470-2045(15)70128-2

21. Morschhauser F., Flinn I.W., Advani R. et al. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS). Lancet Haematol 2019;6(5):e254–e65. DOI: 10.1016/S2352-3026(19)30026-2

22. European Medicines Agency. POLIVY summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/polivy-epar-product-information_en.pdf (accessed 11.09.2020).

23. Sehn L.H., Herrera A.F., Flowers C.R. et al. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2020;38(2):155–165. DOI: 10.1200/JCO.19.00172

24. Sehn L., Hertzberg M., Opat S. et al. Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data. Blood Adv 2022;6(2):533–43. DOI: 10.1182/bloodadvances.2021005794

25. Tilly H., Morschhauser F., Sehn L.H. et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022;386(4):351–63. DOI: 10.1056/NEJMoa2115304

26. Zhang W.R., Liu X., Zhong Q.Z. et al. Prediction of 5-year overall survival of diffuse large B-cell lymphoma on the pola-R-CHP regimen based on 2-year event-free survival and progression-free survival. Cancer Med 2024;13(1):e6899. DOI: 10.1002/cam4.6899

27. Herrera A.F., McCord R., Komes P. et al. Risk profiling of patients with previously untreated diffuse large B-cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): results from the POLARIX study. Blood 2022;140(Suppl 1):1297–300. DOI: 10.1182/blood-2022-157559

28. Проект клинических рекомендаций «Агрессивные нефолликулярные лимфомы – диффузная крупноклеточная В-клеточная лимфома, первичная медиастинальная В-клеточная лимфома, лимфома Беркитта». Доступно по: https://rusoncohem.ru/klinrec/agressivnye-nefollikulyarnye-limfomy-proekt-2021-2022/ (дата доступа: 15.12.2022).

29. Sarkozy C., Sehn L.H. Management of relapsed/refractory DLBCL. Best Pract Res Clin Haematol 2018;31(3):209–16. DOI: 10.1016/j.beha.2018.07.014

30. Fabbri N., Mussetti A., Sureda A. Second-line treatment of diffuse large B-cell lymphoma: evolution of options. Semin Hematol 2023;60(5):305–12. DOI: 10.1053/j.seminhematol.2023.12.001

31. Shi X., Liu X., Li X. et al. Risk stratification for diffuse large B-cell lymphoma by integrating interim evaluation and International Prognostic Index: a multicenter retrospective study. Front Oncol 2021;11:754964. DOI: 10.3389/fonc.2021.754964

32. Pasqualucci L., Trifonov V., Fabbri G. et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011;43(9):830–7. DOI: 10.1038/ng.892

33. Hilton L.K., Scott D.W., Morin R.D. Biological heterogeneity in diffuse large B-cell lymphoma. Semin Hematol 2023;60(5):267–76. DOI: 10.1053/j.seminhematol.2023.11.006

34. Schmitz R., Wright G.W., Huang D.W. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med 2018;378(15):1396–407. DOI: 10.1056/NEJMoa1801445

35. Chapuy B., Stewart C., Dunford A.J. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 2018;24(5):679–90. DOI: 10.1038/s41591-018-0016-8

36. Abramson J.S., Solomon S.R., Arnason J.E. et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of phase 3 TRANSFORM study. Blood 2023;141(14):1675–84. DOI: 10.1182/blood.2022018730

37. Locke F.L., Miklos D.B., Jacobson C.A. et al. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022;386(7):640–54. DOI: 10.1056/NEJMoa2116133